Gautam Mehta, MD, on Precision Oncology: An Overview of the Accelerated Approval Program

April 19, 2022 By The ASCO Post Staff

Gautam Mehta, MD, of the U.S. Food and Drug Administration, discusses how accelerated approval of potentially life-saving cancer therapies has been applied in precision oncology. Although “fast-tracking” drugs presents opportunities and challenges, one possible measure of the program’s success is the fact that, to date, no solid tumor accelerated-approval indications have been withdrawn (Abstract DC06).

Related Content